{"filing":{"accession_number":"0001193125-26-387267","cik":"0001095981","ticker":"PSTV","company_name":"CERENOME, INC.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-04","primary_document":"d382364d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1095981/000119312526387267/d382364d8k.htm"},"events":[{"id":32543,"run_id":29904,"accession_number":"0001193125-26-387267","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Cerenome entered into a Securities Purchase Agreement on September 4, 2026, to issue senior secured convertible notes totaling $21.3 million in aggregate principal amount, with an initial closing providing $3 million in gross proceeds. The notes accrue 8% interest, mature in one year, are convertible into common stock at $2.74 per share (subject to a $0.50 floor), and are secured by a first-priority security interest in substantially all company and subsidiary assets.","company_name":"CERENOME, INC.","ticker":"PSTV","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35736,"accession_number":"0001193125-26-387267","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cerenome entered into a Securities Purchase Agreement on September 4, 2026, to issue senior secured convertible notes totaling $21.3 million in aggregate principal amount, with an initial closing expected to provide $3 million in gross proceeds. The notes accrue 8% interest, mature in one year, are convertible into common stock at $2.74 per share (subject to a $0.50 floor), and are secured by a first-priority security interest in substantially all company and subsidiary assets. This is a material creation of a direct financial obligation distinct from a covenant breach or equity issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:03:47.436177+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32544,"run_id":29904,"accession_number":"0001193125-26-387267","anchor_item_number":"2.03","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.93,"summary":"Cerenome entered into a senior secured financing facility of up to $20 million with 3i, LP, featuring royalty-based repayments and milestone-linked tranches that extend the company's cash runway into 2028. The facility includes an initial funding at closing with future tranches contingent on operational milestones.","company_name":"CERENOME, INC.","ticker":"PSTV","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35737,"accession_number":"0001193125-26-387267","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cerenome entered into a senior secured financing facility of up to $20 million with 3i, LP, with royalty-based repayments and milestone-linked tranches. This creates a direct financial obligation and is disclosed under Item 2.03, which governs creation of direct financial obligations. The facility is material to the registrant's capital structure and extends cash runway into 2028.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:03:47.436177+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35738,"accession_number":"0001193125-26-387267","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities, specifically the potential issuance of shares of Common Stock upon conversion of convertible Notes under a $20 million financing facility with 3i Fund. The press release describes this as \"minimally dilutive to stockholders,\" confirming the equity component. This is a material capital-raising event for a small-cap biotech company with forecasted cash runway extending into 2028 contingent on this financing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:03:47.436177+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35739,"accession_number":"0001193125-26-387267","item_number":"8.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Cerenome entered into a Securities Purchase Agreement for a senior secured financing facility of up to $20 million with royalty-based repayments from 3i, LP. This creates a new direct financial obligation—a debt facility with structured tranches and repayment terms. The company received initial funding at closing with future tranches linked to milestones, and the CFO explicitly states the facility is \"designed to be minimally dilutive to stockholders,\" distinguishing it from equity issuance. This is material as it extends cash runway into 2028 and supports commercial operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:03:47.436177+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35736,"accession_number":"0001193125-26-387267","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cerenome entered into a Securities Purchase Agreement on September 4, 2026, to issue senior secured convertible notes totaling $21.3 million in aggregate principal amount, with an initial closing expected to provide $3 million in gross proceeds. The notes accrue 8% interest, mature in one year, are convertible into common stock at $2.74 per share (subject to a $0.50 floor), and are secured by a first-priority security interest in substantially all company and subsidiary assets. This is a material creation of a direct financial obligation distinct from a covenant breach or equity issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:03:47.436177+00:00","company_name":"CERENOME, INC.","ticker":"PSTV","filing_date":"2026-09-10"},{"id":35737,"accession_number":"0001193125-26-387267","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cerenome entered into a senior secured financing facility of up to $20 million with 3i, LP, with royalty-based repayments and milestone-linked tranches. This creates a direct financial obligation and is disclosed under Item 2.03, which governs creation of direct financial obligations. The facility is material to the registrant's capital structure and extends cash runway into 2028.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:03:47.436177+00:00","company_name":"CERENOME, INC.","ticker":"PSTV","filing_date":"2026-09-10"},{"id":35738,"accession_number":"0001193125-26-387267","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities, specifically the potential issuance of shares of Common Stock upon conversion of convertible Notes under a $20 million financing facility with 3i Fund. The press release describes this as \"minimally dilutive to stockholders,\" confirming the equity component. This is a material capital-raising event for a small-cap biotech company with forecasted cash runway extending into 2028 contingent on this financing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:03:47.436177+00:00","company_name":"CERENOME, INC.","ticker":"PSTV","filing_date":"2026-09-10"},{"id":35739,"accession_number":"0001193125-26-387267","item_number":"8.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Cerenome entered into a Securities Purchase Agreement for a senior secured financing facility of up to $20 million with royalty-based repayments from 3i, LP. This creates a new direct financial obligation—a debt facility with structured tranches and repayment terms. The company received initial funding at closing with future tranches linked to milestones, and the CFO explicitly states the facility is \"designed to be minimally dilutive to stockholders,\" distinguishing it from equity issuance. This is material as it extends cash runway into 2028 and supports commercial operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:03:47.436177+00:00","company_name":"CERENOME, INC.","ticker":"PSTV","filing_date":"2026-09-10"}]}